ProUroCare Medical, Inc. engages in the development of products for the detection and characterization of male prostate disease. The company is headquartered in Eden Prairie, Minnesota and currently employs 2 full-time employees. The company went IPO on 2002-05-28. The firm is focused on its product, a prostate mechanical imaging device called the ProUroScan System. The ProUroScan is an advanced medical imaging system that uses an array of sensors mounted on a rectal probe, a central processing unit and software and image construction algorithms to provide a real time color image of abnormalities in the prostate. The ProUroScan System probe is specially designed for the rectal anatomy to minimize patient discomfort. In addition, it provides mechanical or elasticity imaging, which refers to a non-invasive analysis of tissue movement and displacement. The ProUroScan technique works by computing how tissue moves in response to pressure, thus evaluating its softness or stiffness. Its product also provides two-and three-dimensional prostate images.
최신 재무제표(Form-10K)에 따르면, ProUroCare Medical Inc의 총 자산은 $0이며, 순손실입니다.
PUMD의 주요 재무 비율은 무엇인가요?
ProUroCare Medical Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
ProUroCare Medical Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
ProUroCare Medical Inc 주요 수익원은 Terminals and Related Businesses이며, 최신 수익 발표에서 수익은 11,727,765,075입니다. 지역별로는 China이 ProUroCare Medical Inc의 주요 시장이며, 수익은 5,609,712,776입니다.
ProUroCare Medical Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 ProUroCare Medical Inc의 순손실은 $-2입니다.